About Derma Sciences (NASDAQ:DSCI)
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNASDAQ:DSCI
CUSIP24982750
Phone+1-609-5144744
Debt
Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.02%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20.97%
Return on Equity-17.10%
Return on Assets-12.43%
Miscellaneous
Employees263
Outstanding Shares28,340,000
Derma Sciences (NASDAQ:DSCI) Frequently Asked Questions
What is Derma Sciences' stock symbol?
Derma Sciences trades on the NASDAQ under the ticker symbol "DSCI."
How were Derma Sciences' earnings last quarter?
Derma Sciences Inc (NASDAQ:DSCI) posted its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to the consensus estimate of $22.40 million. Derma Sciences had a negative return on equity of 17.10% and a negative net margin of 20.97%. View Derma Sciences' Earnings History.
Who are some of Derma Sciences' key competitors?
Some companies that are related to Derma Sciences include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Derma Sciences been receiving favorable news coverage?
Media headlines about DSCI stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Derma Sciences earned a news sentiment score of 0.11 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Derma Sciences?
Shares of DSCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Derma Sciences' stock price today?
One share of DSCI stock can currently be purchased for approximately $7.00.
How can I contact Derma Sciences?
Derma Sciences' mailing address is 214 Carnegie Ctr Ste 300, PRINCETON, NJ 08540-6237, United States. The medical instruments supplier can be reached via phone at +1-609-5144744.
MarketBeat Community Rating for Derma Sciences (DSCI)
MarketBeat's community ratings are surveys of what our community members think about Derma Sciences and other stocks. Vote "Outperform" if you believe DSCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Derma Sciences (NASDAQ:DSCI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | Hold |
| Consensus Rating Score: | N/A | N/A | N/A | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Derma Sciences (NASDAQ:DSCI) Consensus Price Target History
Derma Sciences (NASDAQ:DSCI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/18/2017 | Roth Capital | Downgrade | Buy -> Neutral | | N/A |  |
(Data available from 4/21/2016 forward)
Derma Sciences (NASDAQ:DSCI) Earnings History and Estimates Chart
Derma Sciences (NASDAQ DSCI) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/10/2016 | Q316 | ($0.04) | ($0.05) | $23.90 million | $21.80 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.08) | $0.08 | $22.40 million | $22.20 million | View | Listen | |
| 5/11/2016 | Q116 | ($0.13) | ($0.07) | $20.60 million | $20.20 million | View | Listen | |
| 3/16/2016 | Q4 2015 | ($0.39) | ($0.12) | $20.24 million | $20.25 million | View | N/A | |
| 11/9/2015 | Q315 | ($0.43) | ($0.35) | $22.31 million | $22.20 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.43) | ($0.36) | $21.66 million | $22.60 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.46) | ($0.42) | $19.89 million | $19.50 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.46) | ($0.37) | $22.90 million | $22.90 million | View | Listen | |
| 11/10/2014 | Q314 | ($0.43) | ($0.45) | $21.90 million | $20.20 million | View | N/A | |
| 8/7/2014 | Q2 | ($0.46) | ($0.34) | $21.31 million | $20.92 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.28) | ($0.46) | $19.79 million | $19.80 million | View | Listen | |
| 3/14/2014 | Q4 | ($0.36) | ($0.31) | $21.26 million | $20.70 million | View | Listen | |
| 11/13/2013 | Q3 | ($0.44) | ($0.29) | $21.96 million | $22.10 million | View | Listen | |
| 8/12/2013 | Q2 2013 | ($0.45) | ($0.43) | $19.95 million | $18.10 million | View | Listen | |
| 5/16/2013 | Q1 2013 | ($0.37) | ($0.38) | $19.00 million | $18.80 million | View | Listen | |
| 4/1/2013 | Q4 2012 | ($0.31) | ($0.27) | | | View | N/A | |
| 11/12/2012 | Q312 | ($0.37) | ($0.24) | $19.00 million | $19.60 million | View | N/A | |
| 8/14/2012 | Q2 2012 | ($0.23) | ($0.23) | | | View | N/A | |
| 5/15/2012 | Q1 2012 | ($0.16) | ($0.24) | | | View | N/A | |
| 3/29/2012 | Q4 2011 | ($0.11) | ($0.23) | | | View | N/A | |
| 11/11/2011 | Q3 2011 | ($0.11) | ($0.07) | | | View | N/A | |
| 8/16/2011 | Q2 2011 | ($0.09) | ($0.08) | | | View | N/A | |
| 5/11/2011 | Q1 2011 | $0.01 | ($0.08) | | | View | N/A | |
| 3/30/2011 | Q4 2010 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/12/2010 | Q3 2010 | $0.08 | ($0.08) | | | View | N/A | |
| 8/13/2010 | Q2 2010 | ($0.20) | ($0.14) | | | View | N/A | |
| 5/13/2010 | Q1 2010 | | ($0.05) | | | View | N/A | |
| 4/1/2010 | Q4 2009 | | $0.01 | | | View | N/A | |
| 11/16/2009 | Q3 2009 | ($0.08) | $0.02 | | | View | N/A | |
| 8/17/2009 | Q2 2009 | ($0.08) | ($0.11) | | | View | N/A | |
| 5/18/2009 | Q1 2009 | ($0.08) | ($0.15) | | | View | N/A | |
| 4/1/2009 | Q4 2008 | ($0.08) | ($0.11) | | | View | N/A | |
| 11/17/2008 | Q3 2008 | ($0.08) | ($0.14) | | | View | N/A | |
| 8/14/2008 | Q2 2008 | ($0.16) | ($0.26) | | | View | N/A | |
| 4/1/2008 | Q4 2007 | ($0.08) | ($0.54) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Derma Sciences (NASDAQ:DSCI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Derma Sciences (NASDAQ DSCI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.94%
Institutional Ownership Percentage: 58.89%
Derma Sciences (NASDAQ DSCI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/18/2015 | Srini Conjeevaram | Director | Buy | 1,100 | $6.50 | $7,150.00 | | |
| 8/14/2015 | Samuel E Navarro | Director | Buy | 10,000 | $6.51 | $65,100.00 | | |
| 8/13/2015 | Bruce F Wesson | Director | Buy | 10,000 | $6.58 | $65,800.00 | | |
| 8/13/2015 | Edward J Quilty | CEO | Buy | 15,000 | $6.65 | $99,750.00 | | |
| 8/13/2015 | Robert C Cole | Insider | Buy | 5,000 | $6.73 | $33,650.00 | | |
| 6/12/2015 | Brett Hewlett | Director | Sell | 12,000 | $7.17 | $86,040.00 | | |
| 12/15/2014 | Srini Conjeevaram | Director | Sell | 12,500 | $8.49 | $106,125.00 | | |
| 12/4/2014 | C Richard Stafford | Director | Sell | 6,075 | $8.59 | $52,184.25 | | |
| 11/25/2014 | C Richard Stafford | Director | Sell | 1,775 | $8.26 | $14,661.50 | | |
| 11/18/2014 | C Richard Stafford | Director | Sell | 3,250 | $8.59 | $27,917.50 | | |
| 11/17/2014 | C Richard Stafford | Director | Sell | 1,800 | $8.50 | $15,300.00 | | |
| 11/14/2014 | C Richard Stafford | Director | Sell | 5,073 | $8.48 | $43,019.04 | | |
| 9/16/2014 | Barry Wolfenson | Insider | Buy | 3,750 | $7.99 | $29,962.50 | | |
| 5/19/2014 | Barry Wolfenson | Insider | Buy | 11,250 | $8.79 | $98,887.50 | 75,085 | |
| 5/16/2014 | Edward Quilty | CEO | Buy | 10,000 | $8.70 | $87,000.00 | 170,172 | |
| 1/10/2014 | Ra Capital Management, Llc | Insider | Sell | 300,000 | $11.83 | $3,549,000.00 | | |
| 9/3/2013 | C Richard Stafford | Director | Sell | 15,000 | $14.06 | $210,900.00 | 31,723 | |
| 9/3/2013 | John Yetter | CFO | Sell | 12,100 | $14.16 | $171,336.00 | 46,784 | |
| 5/30/2013 | William C Martin | Major Shareholder | Sell | 95,568 | $13.68 | $1,307,370.24 | | |
| 4/29/2013 | Ra Capital Management, Llc | Major Shareholder | Buy | 3,945 | $11.40 | $44,973.00 | | |
(Data available from 1/1/2013 forward)
Derma Sciences (NASDAQ DSCI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Derma Sciences (DSCI) and Fulgent Genetics (FLGT) Head-To-Head Survey
www.americanbankingnews.com - March 3 at 4:32 PM |
| Comparing Digirad (DRAD) and Derma Sciences (DSCI)
www.americanbankingnews.com - January 31 at 5:10 AM |
| Edap Tms (EDAP) & Derma Sciences (DSCI) Head to Head Comparison
www.americanbankingnews.com - January 4 at 11:28 AM |
| Comparing Derma Sciences (DSCI) and Mazor Robotics (MZOR)
www.americanbankingnews.com - December 19 at 5:26 AM |
| Derma Sciences (DSCI) versus Luna Innovations (LUNA) Financial Analysis
www.americanbankingnews.com - December 19 at 3:16 AM |
| Cogentix Medical (CGNT) versus Derma Sciences (DSCI) Head-To-Head Contrast
www.americanbankingnews.com - November 3 at 3:18 AM |
| Critical Comparison: Derma Sciences (DSCI) & Its Competitors
www.americanbankingnews.com - October 10 at 4:28 AM |
 | Wednesday’s Top Biopharma Movers
finance.yahoo.com - October 5 at 10:09 AM |
| Derma Sciences Buys MEDIHONEY® Brand From Long-Term Partner
finance.yahoo.com - October 5 at 10:09 AM |
| Blog Coverage Integra Set to Acquire Derma Sciences; Announced Outlook 2017
finance.yahoo.com - October 5 at 10:09 AM |
| Company News for January 12, 2017
finance.yahoo.com - October 5 at 10:09 AM |
| DERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Integra LifeSciences Holdings Corporation May be Unfair to Shareholders
finance.yahoo.com - October 5 at 10:09 AM |
| Integra LifeSciences Buys Derma Sciences for $204M
finance.yahoo.com - October 5 at 10:09 AM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 10:09 AM |
| DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI) Over the Proposed Sale of the Company to Integra LifeSciences Holdings Corporation
finance.yahoo.com - October 5 at 10:09 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders -- DSCI
finance.yahoo.com - October 5 at 10:09 AM |
| Harwood Feffer LLP Announces Investigation of Derma Sciences Inc.
finance.yahoo.com - October 5 at 10:09 AM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 10:09 AM |
| SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Derma Sciences, Inc. - DSCI
finance.yahoo.com - October 5 at 10:09 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders
finance.yahoo.com - October 5 at 10:09 AM |
| Why One Analyst Sees Almost 40% Upside in Integra LifeSciences
finance.yahoo.com - October 5 at 10:09 AM |
| PerkinElmer (PKI) & Derma Sciences (DSCI) Critical Review
www.americanbankingnews.com - September 24 at 12:20 AM |
| Dextera Surgical (DXTR) & Derma Sciences (DSCI) Head to Head Comparison
www.americanbankingnews.com - September 14 at 12:28 PM |
| Comparing Derma Sciences (DSCI) and its Competitors
www.americanbankingnews.com - September 11 at 4:22 AM |
| Reviewing Derma Sciences (DSCI) & ViewRay (VRAY)
www.americanbankingnews.com - September 3 at 2:12 AM |
| DERMA SCIENCES, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 11:56 AM |
| DERMA SCIENCES, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or F
biz.yahoo.com - February 24 at 11:51 AM |
 | Integra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger Promptly - StreetInsider.com
www.streetinsider.com - February 23 at 9:48 PM |
| Integra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger Promptly
www.streetinsider.com - February 23 at 4:48 PM |
 | INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is ...
www.businesswire.com - January 27 at 6:27 PM |
 | Integra LifeSciences Commences Previously Announced Cash Tender Offer to Acquire Derma Sciences, Inc. - GlobeNewswire (press release)
globenewswire.com - January 26 at 6:05 PM |
| DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 25 at 6:00 PM |
| DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 25 at 6:00 PM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And ... - Business Wire (press release)
www.businesswire.com - January 17 at 10:41 PM |
| DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - January 17 at 5:40 PM |
 | DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI ... - PR Newswire (press release)
www.prnewswire.com - January 15 at 4:40 PM |
| Integra LifeSciences (IART) to Acquire Derma Sciences (DSCI) for $7/Share, or 40% Premium
www.streetinsider.com - January 13 at 10:36 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc ... - Business Wire (press release)
www.businesswire.com - January 12 at 10:35 PM |
 | Integra Buys Derma Sciences for $204M (IART, DSCI)
www.investopedia.com - January 12 at 5:15 PM |
Derma Sciences (NASDAQ:DSCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Derma Sciences (NASDAQ:DSCI) Income Statement, Balance Sheet and Cash Flow Statement
Derma Sciences (NASDAQ DSCI) Stock Chart for Saturday, April, 21, 2018
Loading chart…
